Kangmei Pharmaceutical Co Ltd (SHG:600518) — Market Cap & Net Worth

$2.83 Billion USD  · CN¥19.36 Billion CNY  · Rank #5160

Market Cap & Net Worth: Kangmei Pharmaceutical Co Ltd (600518)

Kangmei Pharmaceutical Co Ltd (SHG:600518) has a market capitalization of $2.83 Billion (CN¥19.36 Billion) as of June 16, 2026. Listed on the SHG stock exchange, this China-based company holds position #5160 globally and #948 in its home market, demonstrating a -7.28% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kangmei Pharmaceutical Co Ltd's stock price CN¥1.40 by its total outstanding shares 13828896690 (13.83 Billion). Review 600518 total debt and obligations to assess the company's total debt and financial obligations.

Kangmei Pharmaceutical Co Ltd Market Cap History: 2015 to 2026

Kangmei Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $32.97 Billion to $2.83 Billion (-20.23% CAGR).

Index Memberships

Kangmei Pharmaceutical Co Ltd is a constituent of 1 market index:

Index Total Market Cap Weight (%) Rank by Market Cap
Shanghai Shenzhen CSI 300
CSI300
$3.99 Trillion 0.07% #185 of 285

Weight: Kangmei Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Kangmei Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Kangmei Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

0.91x

Kangmei Pharmaceutical Co Ltd's market cap is 0.91 times its annual revenue

Industry average: 0.52x Higher than industry average

Latest Price to Earnings (P/E) Ratio

552.30x

Kangmei Pharmaceutical Co Ltd's market cap is 552.30 times its annual earnings

Industry average: 0.02x Higher than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2015 $32.97 Billion $18.07 Billion $2.76 Billion 1.82x 11.96x
2016 $35.18 Billion $21.64 Billion $3.34 Billion 1.63x 10.53x
2017 $44.48 Billion $17.58 Billion $2.15 Billion 2.53x 20.69x
2018 $18.51 Billion $17.07 Billion $374.49 Million 1.08x 49.44x
2019 $7.55 Billion $11.45 Billion -$4.66 Billion 0.66x N/A
2020 $5.42 Billion $5.41 Billion -$31.08 Billion 1.00x N/A
2021 $6.25 Billion $4.15 Billion $7.92 Billion 1.51x 0.79x
2022 $4.45 Billion $4.18 Billion -$2.69 Billion 1.07x N/A
2023 $3.76 Billion $4.87 Billion $102.52 Million 0.77x 36.71x
2024 $4.74 Billion $5.19 Billion $8.57 Million 0.91x 552.30x

Competitor Companies of 600518 by Market Capitalization

Companies near Kangmei Pharmaceutical Co Ltd in the global market cap rankings as of June 16, 2026.

Key companies related to Kangmei Pharmaceutical Co Ltd by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #553 globally with a market cap of $48.78 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #598 globally with a market cap of $45.26 Billion USD ( CN¥309.32 Billion CNY).
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#509 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#553 GALDERMA GROUP AG NYSE:GALDY $48.78 Billion $43.31
#598 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $45.26 Billion CN¥48.49
#626 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €13.60

Kangmei Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, Kangmei Pharmaceutical Co Ltd's market cap moved from $32.97 Billion to $ 2.83 Billion, with a yearly change of -20.23%.

Year Market Cap Change (%)
2026 CN¥2.83 Billion -26.70%
2025 CN¥3.87 Billion -18.38%
2024 CN¥4.74 Billion +25.81%
2023 CN¥3.76 Billion -15.45%
2022 CN¥4.45 Billion -28.80%
2021 CN¥6.25 Billion +15.30%
2020 CN¥5.42 Billion -28.15%
2019 CN¥7.55 Billion -59.23%
2018 CN¥18.51 Billion -58.38%
2017 CN¥44.48 Billion +26.45%
2016 CN¥35.18 Billion +6.70%
2015 CN¥32.97 Billion --

End of Day Market Cap According to Different Sources

On Jun 15th, 2026 the market cap of Kangmei Pharmaceutical Co Ltd was reported to be:

Source Market Cap
Yahoo Finance $2.83 Billion USD
MoneyControl $2.83 Billion USD
MarketWatch $2.83 Billion USD
marketcap.company $2.83 Billion USD
Reuters $2.83 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Kangmei Pharmaceutical Co Ltd

SHG:600518 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.83 Billion
CN¥19.36 Billion CNY
Market Cap Rank
#5160 Global
#948 in China
Share Price
CN¥1.40
Change (1 day)
+1.45%
52-Week Range
CN¥1.38 - CN¥2.20
All Time High
CN¥27.48
About

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical … Read more